SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (2963)8/20/2005 11:21:15 AM
From: Extra Pale  Respond to of 12215
 
Thanks tuck for the article, adds color on Coley & Anaadys HCV programs. Noticed vrtx had a nice boost yesterday mainly attributed to valuation of its HCV phase 1 drug -g-! (both coley and anandys hcv programs are phase 1 as well, interesting situation for what one analyst cited as an $8billion market in 5 years).



To: tuck who wrote (2963)8/20/2005 9:44:41 PM
From: tom pope  Respond to of 12215
 
Thank you, Tuck. Merril allocated me 100 shares of COLY on the offering and I've been wondering whether to throw them out or build to a meaningful position. Maybe I'll do the latter.



To: tuck who wrote (2963)8/22/2005 2:05:31 AM
From: BulbaMan  Respond to of 12215
 
Much thanks for the link Tuck. I found it an excellent backgrounder on the immune system and toll-like receptors. Dynavax is in Berkeley, home of aging hippies such as myself, so it'll be neat if they come up with a successful product.
Hope to see you again some day at another SI beer bash in the not too distant future.
Bulba


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News